20-Year-Old Female Receives Canada’s 51st SynCardia Total Artificial Heart
Canada’s Montreal Heart Institute saves patients dying from end-stage biventricular (both sides) heart failure through implanting the SynCardia Total Artificial Heart as a bridge to a donor heart transplant.
TUCSON, Ariz. – Dec. 10, 2014 – The Montreal Heart Institute recently achieved a milestone through implanting Canada’s 50th SynCardia temporary Total Artificial Heart, as well as the 51st in a 20-year-old woman.
“The SynCardia Total Artificial Heart is the last best option for patients with end-stage biventricular heart failure and for some patients with a combination of complications that prevent implantation of an LVAD (left ventricular assist device),” says Dr. Michel Carrier, a cardiac surgeon at Montreal Heart Institute. “It gives patients the blood flow they need, which helps them be in better shape for their heart transplant.”
Canada’s first implant of the Total Artificial Heart was on May 1, 1986. The Montreal Heart Institute implanted its first Total Artificial Heart on September 29, 1987.
Like a donor heart transplant, the SynCardia Total Artificial Heart is the only approved device that eliminates the source of end-stage biventricular heart failure. It is approved by Health Canada, the FDA (United States) and CE (Europe).
Biventricular heart failure occurs when the heart’s two ventricles (both sides of the heart) can no longer pump enough blood for the patient to survive.
Canada’s 50th SynCardia Total Artificial Heart implant was done September 8, 2014 on a 50-year-old man. He received a donor heart transplant 18 days later.
The young woman received her SynCardia Total Artificial Heart implant on October 6, 2014 and was transplanted on November 11.
Carrier is a pioneer for using the SynCardia Total Artificial Heart in Canada. From 1985 to 1987 he served a fellowship at the University of Arizona Medical Center, working alongside Dr. Jack Copeland, co-founder of SynCardia Systems, Inc. Copeland is widely regarded for his innovative work and training of surgeons in the use of the Total Artificial Heart and patient care.
Since 1986, the overall bridge-to-transplant rate in Canada has averaged 85%.
According to data published in the New England Journal of Medicine (N Engl J Med 2004;351:859-67) from the 10-year pivotal clinical study which led to FDA approval, 79% of patients who received the SynCardia Total Artificial Heart were bridged to transplant. This is the highest bridge-to-transplant rate for any approved heart device in the world.
- Like SynCardia on Facebook
- Follow SynCardia on Twitter
- Connect with SynCardia on LinkedIn
- Share and Discover on Google+
About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
Janelle Drumwright, email@example.com, (520) 547-7463